Press Releases and Story Ideas

Need a doctor or source for your news story?

Contact us for assistance.

Press Releases

Story Ideas

Coronary artery disease is the most common type of heart disease and is the leading cause of death for both men and women in this country. After receiving FDA approval, HonorHealth was first in the country to implant a heart stent that dissolves completely over time, leaving a healed artery that can expand and contract naturally. HonorHealth cardiac researchers spent the last 10 years working with the manufacturer to bring this technology to market, representing a major advance in the interventional treatment of coronary artery disease.
Orthopedic surgical system at HonorHealth Scottsdale Thompson Peak Medical Center helps surgeon perform precise and accurate partial knee replacement surgeries. This technology is for minimally invasive partial knee replacements with no pre-op CT-scan. Robotic-controlled smart instrumentation allows the surgeon to very precisely place an implant that has been selected for the patient's knee. The benefits to the patient is a much faster rehabilitation including shorter hospitalization, quicker recovery time.
On average, someone suffers a stroke every 40 seconds; someone dies of a stroke every four minutes; and 795,000 people suffer a new or recurrent stroke each year. HonorHealth Deer Valley Medical Center earned the Get With The Guidelines®-Stroke Gold-Plus Quality Achievement Award by meeting specific quality achievement measures for the diagnosis and treatment of stroke patients. These measures include aggressive use of medications and risk-reduction therapies aimed at reducing death and disability of stroke patients. One aggressive use of medication is administrating tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke. People who suffer a stroke and receive the drug, tPA, within three hours of the onset of symptoms may recover quicker and are less likely to suffer severe disability.
This new investigational approach – which is much less invasive than bariatric surgery and performed entirely through the patient’s mouth – may help patients feel full sooner during meals, improving their feelings of fullness and reducing hunger cravings so they can control their portions, consume fewer calories and lose weight. This FDA-approved clinical study is to determine the safety and effectiveness of an incision-free, endoscopic weight loss procedure. HonorHealth is the only site in Arizona participating in the study. Individuals with a body mass index (BMI) of between 30 and 40 may be eligible for the trial.
A sensor the size of a quarter can be implanted in heart failure patients at HonorHealth, dramatically improving their lives while reducing hospitalizations and healthcare costs. The implant sends daily data to a cardiologist to alert pending advanced heart failure. The physician can then help the patient take immediate steps to avoid hospitalization and improve their life. Heart failure is a debilitating disease that drastically impacts a person's health and is one of the costliest diseases to manage in the United States.
Breast cancer deaths have decreased by 35 percent since annual mammogram screenings starting at age 40 became the standard recommendation. Now a federal task force wants to change the mammogram recommendation to every other year starting at 50. HonorHealth breast experts believe that early detection is proven to save lives.
An expandable rod developed by a HonorHealth neurosurgeon allows patients who need back surgery to recover quicker and to spend less time in the hospital. Patients with degenerative disc disease who have the rod implanted during minimally invasive surgery are reducing their hospital stay by 63 percent, going from an average of 4.3 days in the hospital to 1.6 days.
A three-drug therapy for patients with advanced pancreatic cancer had amazing results for two of 10 patients: no evidence of the cancer after one year. The pilot clinical trial at the HonorHealth Virginia G. Piper Cancer Center in Scottsdale is now progressing to a clinical trial with 35 patients to determine if the favorable response rate can be confirmed. Pancreatic cancer is aggressive and displays few symptoms until the cancer is advanced.